Summary: Hydroxyurea (HU) has proven hematologic and clinical benefits, especially when escalated to the maximum tolerated dose (MTD). We reviewed clinical data from patients with sickle cell disease (January 2011 to 2016) to determine baseline sociodemographic and laboratory parameters associated with reaching HU MTD without significant delays. In total, 210 patients (mean HU start age, 6.6 y) were included. Initial Kaplan-Meier event analysis showed 1 year to be an inflection point for reaching MTD. In total, 116 patients (55%) reached MTD in <1 year, with 56 (27%) taking > 1 year to reach MTD and 38 (18%) patients not successfully reaching MTD during follow-up. In both crude and adjusted analyses, age at HU start was found to be significantly and inversely associated with reaching MTD within 1 year. The data presented, specifically the inflection point of reaching MTD at 1 year and the association of young HU start age with reaching MTD within a year, suggest that successful achievement of MTD may be facilitated by starting patients on HU at a young age and that older patients should receive additional intervention to attain MTD within 1 year. Patients who do not achieve MTD within a year may need the most extensive intervention.
S
ickle cell disease (SCD) is one of the most common monogenic disorders worldwide, with > 300,000 afflicted children born each year. 1 The disease causes multisystem morbidity and a significant increase in overall mortality, with most SCD-related deaths occurring in childhood in lowresource countries and in adulthood in high-resource countries. 2, 3 One successful therapy for SCD is hydroxyurea (HU), a myelosuppressive agent and potent ribonucleotide reductase inhibitor. Although the exact mechanism remains incompletely understood, the majority of the clinical benefits of HU centers on its ability to increase the amount of fetal hemoglobin (HbF) in red blood cells, thereby decreasing the fraction of intracellular HbS. 4 Addition of HbF to the growing HbS polymer prevents further extension, reducing sickling, increasing red blood cell lifespan, and raising total hemoglobin (Hb). 5 The clinical efficacy of HU therapy in patients with SCD has been well-validated in large, multicenter trials in both adult and pediatric populations. [6] [7] [8] [9] [10] [11] [12] Hematologically, it has been shown that HU causes significant increases in HbF and overall Hb with decreases in white blood cell (WBC) count, absolute neutrophil count (ANC), and reticulocyte count. 4, 11, [13] [14] [15] These increases in HbF and Hb and decreases in WBC and ANC have translated to better clinical outcomes; children on HU therapy have decreased rates of transfusions, pain crises, dactylitis, acute chest events, and overall hospitalizations, and thus may have lower overall mortality. 8, 11, 13, 16 In an individual patient, the hematologic response to HU therapy has been shown to be dose-dependent, with a higher HU dose resulting in higher HbF and Hb values. 10, [15] [16] [17] [18] Importantly, HbF level is a prevailing predictor of the clinical severity of SCD, with low HbF levels associated with higher risk of early death. 3, [19] [20] [21] Further, a higher dose has not been associated with increased toxicity in adults, adolescents, or even very young children. 8, 14, 17 Therefore, although a prospective trial has to date not been published comparing dosage, the widely accepted practice is to treat patients with their maximum tolerated dose (MTD) of HU. In fact, National Heart, Lung, and Blood Institute SCD guidelines provide specific dose-escalation parameters. 22 The principle behind MTD is that the HU dose is quickly escalated until bone marrow suppression becomes evident (typically when the ANC drops below 2.0 to 4.0×10 3 cells/µL or absolute reticulocyte count (ARC) drops below 70 to 200×10 9 cells/L) or when a predetermined maximum HU dose is reached (typically between 30 and 35 mg/kg/d). 22 Despite the large body of evidence for the efficacy and safety of HU at MTD, clinical experience shows that a significant portion of patients with SCD, and especially pediatric patients, do not reach MTD or have a very prolonged escalation period. Drug adherence is the most commonly cited reason for nonescalation or cancellation of HU therapy. 23, 24 Thus, many patients on HU are not receiving optimal therapy at MTD. It is therefore of interest to identify the characteristics of patients who experience significant delays in reaching MTD or do not reach MTD, allowing prospective identification of patients at high risk for HU treatment failure or delay. Thus, the aims of the present study were to (a) quantify the proportion of patients who reach MTD in an appropriate time frame, defined as 1 year, among patients receiving HU at Texas Children's Hospital (TCH) and (b) identify baseline hematologic and sociodemographic characteristics (ie, characteristics at HU start) that are associated with successfully reaching MTD within this time frame.
MATERIALS AND METHODS

Participants
The study was approved by the TCH Institutional Review Board. Patients were identified using a database consisting of all patients prescribed HU for sickle cell anemia (genotypes HbSS and HbS β 0 -thalassemia) between the ages of 6 months and 21 years of age at TCH and who had previously agreed to have their demographic information, laboratory results, and clinical course anonymously analyzed for research purposes. All patients prescribed HU were approached and > 99% agreed to participate. Patients were excluded from the analysis if they met the following criteria: (a) they had started HU before January 1, 2011 or after January 1, 2016; (b) they had started HU at another institution or practice; (c) they were lost to follow-up within 1 year of starting HU.
Dependent Variable (Time to MTD)
The aim of this study was to determine sociodemographic and hematologic characteristics associated with our dependent/outcome variable, time to MTD. Time to MTD is defined as the amount of time between the initial HU start date and the date at which MTD was achieved. The MTD date was the date at which the individual provider determined the patient had reached MTD. Data were collected via review of HU prescriptions and patient charts. At each visit the provider would indicate whether HU dose escalation was warranted, with the following scenarios: (a) If affirmative for HU escalation, the patient was determined to not be at MTD. (b) If negative and the provider charted the patient was at MTD or patient was at a HU dose of ≥ 30 mg/kg/d, the patient was determined to be at MTD. (c) If negative and the provider indicated dose escalation would be warranted in the future, the patient was determined to not be at MTD. 
Independent Variables
HU start age was defined as the age at which HU therapy was first initiated and was identified by chart review of provider notes and prescriptions. If patients started, stopped, and restarted HU therapy, the start age remained their initial start age and not subsequent restart ages. Baseline (ie, before HU initiation) laboratory values, including Hb, HbF, HbS, WBC, ANC, and ARC were collected on all patients; these laboratory results were readily available via chart review, as it is institutional practice to collect these data before initiation of HU therapy. The independent variables, both socioeconomic and hematologic, were chosen a priori; specifically, Hb, HbF, HbS, WBC, ANC, and ARC were chosen, as these are hematologic parameters that are both monitored and affect the clinical status of patients on HU therapy.
Statistical Analysis
We performed a survival analysis in which the outcome was time to MTD event (in years). We created a KaplanMeier curve using the complete sample (n = 210). A critical time point at 1 year of follow-up was detected in the Kaplan-Meier curve, which supported our a priori time frame of 1 year on the basis of the above clinical reasoning, and was used as a dichotomization point in our subsequent analyses.
The characteristics of participants were explored via means and standard deviations as well as simple frequencies and percentages, in the complete sample and after dichotomization by "reaching MTD within 1 year of HU therapy" (n = 116) or "not reaching MTD within 1 year of HU therapy" (n = 94). Dichotomist variables (sex, race, and SCD genotype) were compared between both groups using the Fisher Exact test. Continuous variables (age, body mass index, Hb, HbS, HbF, WBC, ANC, and ARC; all measured at baseline) were analyzed by 1-way analysis of variance.
We then estimated crude and adjusted risk ratios (RR) of reaching MTD within 1 year, using simple and multiple logPoisson robust models. 25 First, we estimated crude RR for each baseline covariate of interest: sex, age, race, body mass index, Hb type, Hb, HbS, HbF, WBC, ANC, and ARC. Next, we performed 4 models for obtaining adjusted RR and compared these models using Akaike Information Criterion (AIC). We started with null and full models, the last containing all the mentioned covariates (called model 1). Model 2 was obtained via a backward stepwise procedure, using thresholds of P = 0.10 for removing variables and P = 0.05 for adding variables to the model. Model 3 was the model 2 plus sex and ethnicity (selected for being universal confounders).
As there were concerns about the potential mediation effect of HbF in the relationship between age at baseline and reaching MTD within 1 year, we performed a mediation analysis as well. 26 Specifically, we performed a model-based causal mediation analysis wherein age was the independent variable, MTD was the outcome, and HbF was the mediator. 27 We began with the mediation model (linear regression, outcome = HbF, predictor = age) and then the outcome model (log-Poisson robust regression, outcome = MTD, predictors = age and HbF). After that, we summarized these results into the average causal mediation effects (ACME) and the average direct effects (ADE), and with testing determined that they were significantly different from 0. We reproduced a new similar analysis, but added the rest of the covariates as predictors, in both mediation and outcome models. As the main predictor is continuous (age), we performed both analyses (without and with covariates) comparing sequentially different levels of age (from 0 against 1 to 7 against 8).
We extended the initial survival analysis by drawing Kaplan-Meier failure curves stratified by 2 groups (age below 8 y and age above 8 y), keeping the original observation period of follow-up (up to 5.7 y, as we did with the first figure) . Here, we performed a Log-Rank test for comparing both survival curves. The cut point of 8 years was established after a sequential revision of different cut points (one by one, from 1 to 17). We stratified age by the first proposed cut point; we then ran a Log-Rank test and observed its P-value. We repeated this with all cut points (from 2 to 17 years of age). The cut point with the smallest P-value was selected; it corresponded to a HU start age of 8 years.
We defined P < 0.05 as significant, performed confidence intervals at 95% (95% CI) using robust SEs, and provided Wald test results for all estimated parameters. We used Stata version 14.2 (StataCorp, Special Edition; College Station, TX) and R version 3.3.3 (only for the mediation analysis) as our analysis software.
RESULTS
A total of 210 patients were included in the data analysis, with 48% of the subjects being male individuals and 92% African American. The mean age at HU start was 6.6 years (SD = 4.8) and 22/210 (10%) started HU at above 13 years of age. Table 1 shows the general distribution of the children's demographic and hematologic characteristics (for the complete sample of 210), stratified by reaching MTD within 1 year (n = 116) or not (n = 94). Two results from this table merit special attention: mean of age at baseline (P = 0.02), which is higher in the second group (n = 94), and HbF at baseline (P = 0.02), which is higher in the first group (n = 116). In total, 116 of the 210 patients analyzed (55%) reached MTD in <1 year, 56 (27%) patients reached MTD in > 1 year, and 38 (18%) patients had not yet reached MTD as of December 31, 2016 . Figure 1A , a Kaplan-Meier failure curve for event (reaching MTD) versus time since HU initiation (in years) displays the raw data for time to MTD and shows an inflection point at 1 year. As previously mentioned, as per TCH guidelines, the starting dose of HU was 20 mg/kg/d. Although the highest HU dose allowed by our guidelines was 35 mg/kg/d, the average MTD dose for the cohort was lower, at 25.5 mg/kg/d. Table 1 shows the baseline (ie, before HU initiation) characteristics for the study participants, for the whole sample, and also subdivided by MTD status.
Bold-statistically significant (P < 0.05).
Income is the median family income. WBC, ANC-10 3 cells/µL. ARC-10 6 cells/µL. There are no missing data in this sample (n = 210). *Not reached until the finish of the first 1-year observation period; however, some of these cases reached MTD after 1 year.
†ANOVA 1-way for continuous variables and the Fisher Exact for dichotomic variables.
ANC indicates absolute neutrophil count; ANOVA, analysis of variance; ARC, absolute reticulocyte count; BMI, body mass index; HU, hydroxyurea; MTD, maximum tolerated dose; thal, thalassemia; WBC, white blood cell. Table 2 shows a relationship between age at baseline and the outcome, which is visible in the crude estimate and 2 of 3 adjusted estimates. Statistically, the best model is model 2, which has the smallest AIC (370.99). For this model, an adjusted RR = 0.97 (95% CI, 0.94-0.99; P = 0.02) explains that per every 1 year of increase in age at baseline (ie, age at HU initiation) the chance of reaching MTD within 1 year decreases by 3% (on average). This estimate is still the same after controlling for confounders (see model 3).
As seen in the previous literature, HbF at baseline and age at baseline showed a strong inverse association (β = −0.79, 95% CI, −0.95 to −0.64; P < 0.001). The modelbased causal mediation analysis showed that there is no mediation effect of HbF in the relationship between age at baseline and reaching MTD up to 1 year of follow-up. After performing all the mediation and outcome models, with and without covariates, and checking them sequentially for different ages (from 0 against 1, to 7 against 8 in years), all the P-values were > 0.05 for all the indicators of interest: ACME, ACME average, ADE, and ADE average. Figure 1B provides the best age cut point (8 y) for showing the evolution of reaching MTD before and beyond the threshold of 1 year. As seen in the figure, children aged 8 years or below at initiation of HU therapy are more likely to reach MTD in a year as compared with the older cohort (Log-rank test: χ 2 = 4.4; P = 0.04). However, 85% (115/136) of the below 8-year age cohort and 79% (57/74) of the above 8-year age cohort reached MTD within the entire follow-up period. As such, in our cohort, age did not affect the overall likelihood of reaching MTD.
DISCUSSION
HU has well-proven hematologic and clinical benefits, especially when escalated to the MTD. The results of this study show that even in a large academic institution, which often has resources for optimizing patient care unavailable in other settings such as those for social workers, care managers, and other support staff, only 55% of the 210 patients analyzed reached MTD in <1 year. Our results support the idea that 1 year after HU treatment initiation is a critical point in the evolution of patients in terms of reaching MTD (Fig. 1A) . In this scenario, age at HU initiation plays a central role: (a) the older a child starts his/her treatment, the lower their chances of reaching MTD within 1 year of HU treatment initiation; (b) children aged 8 years or younger have a greater chance of reaching MTD within 1 year of HU treatment initiation. In other words, younger children are more likely to reach MTD within 1 year as compared with older children.
Because of the potential toxicities of administering HU, a myelosuppressive agent, researchers and clinicians have historically been cautious to administer this therapy to children and especially to young children and infants. Indeed, the first trials excluded pediatric patients. 21, 28 However, as the clinical benefits and safety profile of HU became evident in adults, HU therapy was expanded to include children, with pediatric data showing HU to be very well tolerated. 4 If present, side effects tend to be mild, with pain, headaches, abdominal discomfort, and nausea being most commonly reported. 14 Growth, development, 
370.99 376.14 Model 1 is the full model, which includes all the variables listed in the first column. Model 2 is the one obtained by the stepwise procedure described in the methods section, including-in this case-just 1 variable: age at baseline. Model 3 is the model 2 plus sex and ethnicity. Robust variance was used for estimating SEs.
Baseline is defined by the initiation of HU treatment. The outcome is reaching MTD within 1 year. Income is the median family income. WBC -10 3 cells/µL, ANC-10 3 cells/µL. ARC-10 6 cells/µL. There are no missing data in this sample (n = 210). Bold-statistically significant (P < 0.05). *Wald test. †For null model the AIC is 371.70. AIC indicates Akaike Information Criterion; ANC, absolute neutrophil count; ARC, absolute reticulocyte count; BMI, body mass index; HU, hydroxyurea; MTD, maximum tolerated dose; ref, reference; RR, risk ratio; thal, thalassemia; WBC, white blood cell; 95% CI, 95% confidence interval. and sexual maturation do not seem to be adversely affected. 14, 17, 28, 29 Given that a decrease in ANC is a known, predictable, and desired "toxicity" of HU therapy and the baseline immunosuppressed state of patients with SCD, infection risk has been a valid concern. However, all the published literature suggest that there is no increased risk of infection. 4, 11, 16, 30 Data among very young children and infants have been equally reassuring. The HUSOFT trial, which enrolled young children from ages 6 to 28 months, and the subsequent extension study both showed that HU was tolerated well, with no increased rate in severe toxic events, and sepsis rates comparable to previous controls. 11, 15 Further, BABY HUG, a randomized controlled trial of HU in children aged 9 to 18 months was published in the Lancet in 2011, concluding that "on the basis of safety and efficacy data, HU can now be considered for all very young children with sickle-cell anemia." 8 For these reasons, the current guidelines recommend offering HU therapy to all children with SCD starting at 9 months, regardless of symptoms or clinical status. 22 The safety and efficacy data previously published on HU therapy in very young children in conjunction with the present finding that children of younger age are more likely to reach MTD in a year suggest that every effort should be made to start HU therapy in very young children. One potential reason young children were more likely to reach MTD is adherence; in SCD and in other chronic diseases such as diabetes, 31 cancer, 32 and human immunodeficiency virus, 33 older children and adolescents are more likely to be nonadherent with their medications, and adherence is the often-cited barrier to proper HU therapy. 34 An advantage of the current data is that it comes from outside the confines of a clinical trial, in which study participants are often monitored and followed-up more closely than patients in typical clinical practice. Published data have indeed shown that escalation to MTD often occurs more rapidly in these trials than that found in our study. For example, the following trials, SWiTCH (90% reached, with a mean of 32 wk to reaching MTD), 35 HUG-KIDS (81%, mean 224 d), 14 and TWiTCH (95%, based on laboratory parameters, mean appeared to be 40 wk), 36 all had mean escalation times of <1 year. As such, the adherence and resultant consequences of the current study are more applicable to a typical clinical setting.
In such a setting, there are often delays in initiating or escalating HU. Although not specifically analyzed in this study, potential causes of delay in reaching MTD include the following: (1) difficulties in developing a routine that incorporates daily administration, (2) missed appointments, and, (3) especially in young children, delays in dose escalation from myelosuppression secondary to viral illnesses. Further, not every child's MTD is 35 mg/kg/d; for our cohort, the average MTD dose was 25.5 mg/kg. This dose is similar to MTD doses in previously published trials, including sustained MTD (MTD dose 25.9 mg/kg), 17 TCD Reduction (27.9), 37 Toddler HUG (28.0), 7 HUSTLE (25.1), 19 and SWiTCH (25.4) . 35 This interpatient variability is another reason we chose to use time to MTD as a dichotomous rather than continuous variable, as differences in HU MTD dose are likely to be multifactorial, involving genetic variation, 38, 39 and beyond the scope of this study. Given these real-world challenges, we believe that reaching MTD within the inflection point of 1 year is a reasonable and achievable goal.
Beyond starting HU at a young age, the data presented suggest that additional inventions to optimize HU therapy should be targeted to older children and children who take > 1 year to reach MTD. Reminders sent via text message approximately double medication adherence in other chronic diseases; 40 similar interventions have been beneficial for HU therapy adherence in patients with SCD and could be areas of targeting intervention, especially older children with smart phones or those taking a daily medicine for the first time. 41 Incorrect dosing and fear of side effects of medication are 2 reported barriers to proper medication among pediatric patients with SCD; 42 thus, additional education on these topics specifically targeted at older patients or patients not yet at MTD after 1 year of HU therapy could improve outcomes.
Other studies have found parents to be hesitant toward HU, given the potential side effects, fear of cancer, not wanting to participate in required laboratory monitoring and follow-up, or concern that HU will not be efficacious; 43 these potential confounders have been previously reported and thus were not examined in the present study. In addition, provider-level variability and barriers are important aspects that can impact medication-prescribing habits and overall adherence, although not analyzed in the current study, as the practice since 2011 of the TCH hematology center has been to encourage HU therapy at MTD for all patients. Despite this encouragement, HU compliance may have been poor among some patients, and we did not use a specific measure of quantifying HU compliance (such as pill counting or prescription monitoring), which represents a limitation to the study. Importantly, as a retrospective analysis, associations, not causation, can be concluded. Caution should be applied when extrapolating the results to different patients and patient populations, especially those patients being cared for in settings with different resources than a large, urban, academic institution such as TCH. Thus, while these results may be applicable to the current patient population, these findings may not necessarily be predictive or generalizable.
The time to MTD was provider rather than laboratory determined. Although it would have been simpler to use strict hematologic or HU-dosing parameters, the accuracy of the study would have been compromised for several reasons. First and most important, the goal of our analysis was to report the actual time it takes to reach the patient's specific MTD. Although clinicians may rely on laboratory data, the decision whether to escalate HU dosing is ultimately the provider's (outside a protocol-based clinical trial). For example, children often undergo suppression of hematologic counts for reasons other than HU (eg, viral suppression); using only laboratory criteria could misclassify these children as at MTD. Alternatively, although the TCH Hematology Center's practice guidelines define MTD as ANC (2.0 to 4.0×10 3 cells/µL), ARC (70 to 200×10 9 cells/L, and the maximum HU dose (35 mg/kg), there exists variability between providers. Thus, the decision to not use numeric cut-offs helps avoid penalizing patients who were at MTD as per their provider, despite not meeting strict laboratory criteria. As such, in clinical practice, the time to MTD is not the time until reaching specific laboratory parameters, but rather the time until the provider determines the patient is at MTD, which we have attempted to replicate in this analysis. Further, these specific data-time to MTD in clinical settings-are absent from the published literature and therefore warrants attention.
Our data show that there is a subset of pediatric patients with SCD who do not reach MTD and many who
